Insmed Incorporated (NASDAQ:INSM) Stake Lifted by Park Avenue Securities LLC

Park Avenue Securities LLC grew its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 38.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,036 shares of the biopharmaceutical company's stock after acquiring an additional 3,081 shares during the period. Park Avenue Securities LLC's holdings in Insmed were worth $842,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in INSM. Elequin Capital LP purchased a new stake in Insmed during the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC boosted its holdings in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares in the last quarter. NBC Securities Inc. purchased a new stake in Insmed during the first quarter worth about $49,000. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Finally, Versant Capital Management Inc lifted its holdings in shares of Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares in the last quarter.

Analysts Set New Price Targets

INSM has been the topic of several recent research reports. Mizuho upped their price target on shares of Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insmed in a report on Tuesday. UBS Group cut their price objective on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lifted their price objective on Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Truist Financial lifted their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $104.81.

Insmed Stock Up 1.9%

Shares of INSM traded up $1.85 during trading on Friday, reaching $98.73. The company's stock had a trading volume of 5,318,455 shares, compared to its average volume of 2,164,284. The company has a fifty day moving average of $71.41 and a two-hundred day moving average of $73.61. Insmed Incorporated has a twelve month low of $60.40 and a twelve month high of $100.00. The company has a market cap of $17.98 billion, a price-to-earnings ratio of -17.66 and a beta of 0.80. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period in the previous year, the company earned ($1.06) earnings per share. The business's revenue for the quarter was up 22.9% on a year-over-year basis. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, insider Martina M.D. Flammer sold 9,925 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the sale, the insider now directly owns 86,596 shares of the company's stock, valued at approximately $5,669,440.12. This represents a 10.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at approximately $16,412,107.84. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 319,932 shares of company stock valued at $25,733,693 in the last three months. Corporate insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.